Please login to the form below

Not currently logged in
Email:
Password:

Akinion appoints Dr Richard Jones as CEO

He joins the biotech firm from GlaxoSmithKline

Akinion Dr Richard JonesDr Richard Jones has been appointed as chief executive officer for privately-held Swedish biotech firm Akinion Pharmaceuticals.

He brings more than 20 years of pharmaceutical industry experience to the company and arrives from Novartis where he was vice president, medicines commercialisation leader, haematology, global oncology.

Before that Dr Jones served at GlaxoSmithKline, where he was most recently VP, global haematology medicines commercialisation leader.

In that role he was responsible for delivering the big pharma company's global haematology strategy, and prior to he served at Sanofi Genzyme as director and M&A transition lead for its transplant and oncology global business unit.

In his new role at Akinion Pharmaceuticals Dr Jones will oversee a company focused on acute myeloid leukaemia and its lead candidate drug AKN-028, a small molecule kinase inhibitor currently in a phase I/II clinical trial.

27th January 2016

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Digitas Health

Digitas Health is the only digital-at-the-core brand agency designed to connect today's healthcare brands with today's healthcare consumers and professionals....

Latest intelligence

Australian Flu and the dilemma of naming diseases
...
Wearables and Healthcare
What place do wearables have in affecting actual patient health outcomes and can they contribute to the NHS’s sustainability agenda? Or are they just the latest fad?...
What does a future-proof rep look like?
Businesses can no longer afford to push ahead with the traditional Key Account Management model....

Infographics